Vivek Subbiah: Excited and honored to attend the San Antonio Breast Conference meeting

Vivek Subbiah shared on LinkedIn:

“Excited and honored to attend the San Antonio Breast Conference meeting!

Tissue Agnostic precision medicine takes center stage tomorrow.

Huge thanks to the organizers at San Antonio Breast Conference American Association for Cancer Research, AACR Journals for inviting me to deliver a lecture on “Tumor agnostic Precision Oncology” and share my insights in precision medicine at SABC23.

Looking forward for a fantastic session and workshop with an amazing panel of speakers Drs. Mia Levy, Joshua Z. Drago, and Marleen Kok and Sangeetha M. Reddy at SABCS23 (December 5).”

Source: Vivek Subbiah/LinkedIn

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center. Dr. Vivek Subbiah has served as the principal investigator in over 100 phase I/II trials and co-investigator in over 200 clinical trials and is known for his leadership in several first-in-human and practice-changing studies that directly led to approvals from the FDA, European Medicines Agency, and other agencies across the world. He is an expert in tumor agnostic precision oncology and leads the BRAF and RET tissue agnostic studies to FDA approval.